For the quarter ended September 2025, Becton Dickinson (BDX Quick QuoteBDX - Free Report) reported revenue of $5.89 billion, up 8.3% over the same period last year. EPS came in at $3.96, compared to $3.81 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $5.89 billion, representing a surprise of +0.04%. The company delivered an EPS surprise of +1.02%, with the consensus EPS estimate being $3.92.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Becton Dickinson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- BD Interventional- Surgery- United States: $290 million versus $294.08 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.9% change.
• Revenues- BD Medical- Medication Management Solutions- United States: $780 million versus the four-analyst average estimate of $801.24 million. The reported number represents a year-over-year change of +4.8%.
• Revenues- BD Interventional- Urology and Critical Care- United States: $341 million compared to the $331.6 million average estimate based on four analysts. The reported number represents a change of +11.4% year over year.
• Revenues- BD Interventional- Surgery- International: $110 million versus $96.79 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +23.6% change.
• Revenues- BD Interventional: $1.37 billion versus $1.35 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.5% change.
• Revenues- BD Interventional- Surgery: $400 million versus the five-analyst average estimate of $391.29 million. The reported number represents a year-over-year change of +8.7%.
• Revenues- BD Interventional- Peripheral Intervention: $530 million versus $532.03 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.
• Revenues- BD Interventional- Urology and Critical Care: $437 million compared to the $422.9 million average estimate based on five analysts. The reported number represents a change of +12.1% year over year.
• Revenues- BD Medical- Advanced Patient Monitoring: $276 million compared to the $268.69 million average estimate based on five analysts.
• Revenues- BD Medical: $3.16 billion compared to the $3.19 billion average estimate based on five analysts. The reported number represents a change of +11.2% year over year.
• Revenues- BD Medical- Medication Management Solutions: $974 million versus the five-analyst average estimate of $1.01 billion. The reported number represents a year-over-year change of +3.7%.
• Revenues- BD Life Sciences- Biosciences: $387 million compared to the $404.33 million average estimate based on five analysts. The reported number represents a change of -2.5% year over year.

View all Key Company Metrics for Becton Dickinson here>>>

Shares of Becton Dickinson have returned -9% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.